Humacyte (HUMA) Other Operating Expenses (2020 - 2026)

Humacyte (HUMA) reported Other Operating Expenses of $2.0 million for Q1 2026, up 1286.39% year-over-year from $147000.0 in Q1 2025, and down 77.56% quarter-over-quarter from $9.1 million in Q4 2025.

Humacyte (HUMA) Other Operating Expenses (2020 - 2026) Analysis & Trends

Humacyte (HUMA) has 3 years of Other Operating Expenses data on file, last reported at $2.0 million in Q1 2026.

  • Other Operating Expenses for Q1 2026 came in at $2.0 million, up 1286.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.6 million (up 7786.39% YoY), and the FY2025 annual result was $9.7 million, changed N/A from the prior year.
  • Other Operating Expenses slipped to $2.0 million in Q1 2026 per HUMA's latest filing, from $9.1 million in the prior quarter.
  • Over five years, Other Operating Expenses peaked at $9.1 million in Q4 2025 and troughed at $147000.0 in Q1 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 723,416.35 Bn 723,416.32 Bn -
2 Belite Bio 57,340.00 Bn 57,340.00 Bn -
3 Quantum Biopharma 19,125.08 Bn 19,125.08 Bn -
4 Legend Biotech 3,262.00 Bn 3,261.71 Bn 242.10 Mn
5 Akari Therapeutics 1,789.67 Bn 1,789.67 Bn -
6 Evaxion A 1,480.39 Bn 1,480.37 Bn -
7 Psyence Biomedical 241.78 Bn 241.78 Bn -
8 Vertex Pharmaceuticals 113.54 Bn 106.29 Bn 2.59 Bn
9 Abivax 94.26 Bn 94.26 Bn -
10 Humacyte 267.09 Mn 218.55 Mn -1.54 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 2.04 Mn
Dec 31, 2025 9.08 Mn
Sep 30, 2025 260,000.00
Jun 30, 2025 213,000.00
Mar 31, 2025 147,000.00
Dec 31, 2020 1.65 Mn
Sep 30, 2020 -99,044.00